117 related articles for article (PubMed ID: 37830976)
1. Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand.
Kategeaw W; Nakkam N; Kiertiburanakul S; Sukasem C; Tassaneeyakul W; Chaiyakunapruk N
J Med Econ; 2023; 26(1):1330-1341. PubMed ID: 37830976
[TBL] [Abstract][Full Text] [Related]
2. Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions.
Iamsumang W; Chanprapaph K; Sukasem C; Satapornpong P; Thadanipon K; Suchonwanit P; Jantararoungtong T; Anuntrangsee T
Dermatology; 2023; 239(6):966-975. PubMed ID: 37793359
[TBL] [Abstract][Full Text] [Related]
3. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
Wang CW; Tassaneeyakul W; Chen CB; Chen WT; Teng YC; Huang CY; Sukasem C; Lu CW; Lee YS; Choon SE; Nakkam N; Hui RC; Huang YH; Chang YC; Lin YY; Chang CJ; Chiu TM; Chantratita W; Konyoung P; Lee CN; Klaewsongkram J; Rerkpattanapipat T; Amornpinyo W; Saksit N; Rerknimitr P; Huang YH; Lin SH; Hsu CK; Chan CC; Lin YJ; Hung SI; Chung WH;
J Allergy Clin Immunol; 2021 Apr; 147(4):1402-1412. PubMed ID: 32791162
[TBL] [Abstract][Full Text] [Related]
4. Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions.
Nakkam N; Saksit N; Konyoung P; Amornpinyo W; Khunarkornsiri U; Purimart D; Pattanacheewapull O; Naewla T; Wattanachai P; Khaeso K; Chumworathayi P; Tassaneeyakul W
Drug Metab Pharmacokinet; 2022 Dec; 47():100480. PubMed ID: 36379177
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
[TBL] [Abstract][Full Text] [Related]
7. Genetic Association of Co-Trimoxazole-Induced Severe Cutaneous Adverse Reactions Is Phenotype-Specific: HLA Class I Genotypes and Haplotypes.
Sukasem C; Pratoomwun J; Satapornpong P; Klaewsongkram J; Rerkpattanapipat T; Rerknimitr P; Lertpichitkul P; Puangpetch A; Nakkam N; Konyoung P; Khunarkornsiri U; Disphanurat W; Srisuttiyakorn C; Pattanacheewapull O; Kanjanawart S; Kongpan T; Chumworathayi P; Saksit N; Bruminhent J; Tassaneeyakul W; Chantratita W; Pirmohamed M
Clin Pharmacol Ther; 2020 Nov; 108(5):1078-1089. PubMed ID: 32452529
[TBL] [Abstract][Full Text] [Related]
8. Integrating real-world data in cost-effectiveness analysis of universal HLA-B*15:02 screening in Malaysia.
Chong HY; Lim KS; Fong SL; Shabaruddin FH; Dahlui M; Mei Lai PS; Ng CC; Chaiyakunapruk N
Br J Clin Pharmacol; 2023 Nov; 89(11):3340-3351. PubMed ID: 37294011
[TBL] [Abstract][Full Text] [Related]
9. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions.
Kongpan T; Mahasirimongkol S; Konyoung P; Kanjanawart S; Chumworathayi P; Wichukchinda N; Kidkeukarun R; Preechakul S; Khunarkornsiri U; Bamrungram W; Supharatwattanakun B; Mootsikapun P; Kwangsukstid S; Denjanta S; Vannaprasaht S; Rungapiromnan W; Suwankesawong W; Tassaneeyakul W; Tassaneeyakul W
Pharmacogenet Genomics; 2015 Aug; 25(8):402-11. PubMed ID: 26086150
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
[TBL] [Abstract][Full Text] [Related]
11. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV.
Turongkaravee S; Praditsitthikorn N; Ngamprasertchai T; Jittikoon J; Mahasirimongkol S; Sukasem C; Udomsinprasert W; Wu O; Chaikledkaew U
Clinicoecon Outcomes Res; 2022; 14():447-463. PubMed ID: 35832304
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
[TBL] [Abstract][Full Text] [Related]
18. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
[TBL] [Abstract][Full Text] [Related]
19. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
20. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population.
Tempark T; Satapornpong P; Rerknimitr P; Nakkam N; Saksit N; Wattanakrai P; Jantararoungtong T; Koomdee N; Mahakkanukrauh A; Tassaneeyakul W; Suttisai S; Pratoomwun J; Klaewsongkram J; Rerkpattanapipat T; Sukasem C
Pharmacogenet Genomics; 2017 Dec; 27(12):429-437. PubMed ID: 28885988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
